BackMerckInc Overview
Merck & Co Inc

MerckInc Target Price

Analysts' average 12-month price target for MerckInc is $150.

Get informed when a big investor buys or sells

+ Follow

Share Price

$148.01

Average Target Price

$152.883.3% upside

25 analysts in the last 4 months

High: $180 | Low: $105

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-11Berenberg BankLuisa Hector$1377.4% downsideOpen
2026-09-10HSBC$17216.2% upsideOpen
2026-09-09Leerink Partners$1618.8% upsideOpen
2026-09-08GuggenheimVamil Divan$17014.9% upsideOpen
2026-09-04Wells Fargo$17014.9% upsideOpen
2026-08-25Argus ResearchJasper Hellweg$17014.9% upsideOpen
2026-08-25Wolfe ResearchAlexandria Hammond$18021.6% upsideOpen
2026-08-21Goldman Sachs$1608.1% upsideOpen
2026-08-20BMO Capital$17014.9% upsideOpen
2026-08-20UBS$17518.2% upsideOpen
2026-08-20RBC Capital$1501.3% upsideOpen
2026-08-20UBSMatthew Weston$1501.3% upsideOpen
2026-08-19Morgan Stanley$17920.9% upsideOpen
2026-08-12Daiwa$1433.4% downsideOpen
2026-08-11Argus ResearchJasper Hellweg$1452% downsideOpen
2026-08-05Morgan StanleyTerence Flynn$11621.6% downsideOpen
2026-08-05GuggenheimVamil Divan$1461.4% downsideOpen
2026-07-29BarclaysEmily Field$1501.3% upsideOpen
2026-07-27BernsteinCourtney Breen$10529.1% downsideOpen
2026-07-13BMO Capital$1424.1% downsideOpen
2026-07-13GuggenheimVamil Divan$1452% downsideOpen
2026-07-06HSBCRajesh Kumar$1501.3% upsideOpen
2026-06-30Jefferies$1414.7% downsideOpen
2026-06-29Scotiabank$1554.7% upsideOpen
2026-06-02GuggenheimVamil Divan$1405.4% downsideOpen
2026-05-01Morgan StanleyTerence Flynn$11224.3% downsideOpen
2026-03-12Wells FargoMohit Bansal$1501.3% upsideOpen
2026-02-24RBC CapitalTrung Huynh$1424.1% downsideOpen
2026-02-13Deutsche BankJames Shin$1501.3% upsideOpen
2026-02-04Goldman SachsAsad Haider$13310.1% downsideOpen
2026-02-04BMO Capital$1358.8% downsideOpen
2026-02-04Bernstein$10032.4% downsideOpen
2026-02-03Scotiabank$1368.1% downsideOpen
2026-01-27Cantor Fitzgerald$11621.6% downsideOpen
2026-01-08Wolfe Research$1358.8% downsideOpen
2026-01-07UBS$13012.2% downsideOpen
2025-12-18BMO Capital$13012.2% downsideOpen
2025-12-12Morgan Stanley$10231.1% downsideOpen
2025-12-10HSBCRajesh Kumar$12018.9% downsideOpen
2025-12-05Guggenheim$12217.6% downsideOpen
2025-12-04ScotiabankLouise Chen$12018.9% downsideOpen
2025-12-02Goldman SachsAsad Haider$12018.9% downsideOpen
2025-11-03Morgan StanleyTerence Flynn$10032.4% downsideOpen
2025-09-17Berenberg BankLuisa Hector$9039.2% downsideOpen
2025-07-10Morgan StanleyTerence Flynn$9833.8% downsideOpen
2025-04-25BMO CapitalEvan Seigerman$8244.6% downsideOpen
2025-02-05Morgan StanleyTerence Flynn$10628.4% downsideOpen
2024-12-02BernsteinCourtney Breen$11025.7% downsideOpen
2024-11-15JefferiesAkash Tewari$1480% upsideOpen
2024-11-01BMO CapitalEvan David Seigerman$1368.1% downsideOpen

MerckInc (MRK) FAQ

MerckInc's target price stands at $150. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $150 for MRK implies 3.3% upside versus today's price ($148.01). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how MerckInc's target price evolved across reporting periods, while the comparison chart places MRK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. MerckInc's reading of $150 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.